Update on the Canadian Diabetes Association 2008 clinical practice guidelines
|
|
- Susan Davis
- 5 years ago
- Views:
Transcription
1 Update on the Canadian Diabetes Association 2008 clinical practice guidelines Onil K. Bhattacharyya MD PhD CCFP Elizabeth A. Estey MA Alice Y.Y. Cheng MD FRCPC Rates of diabetes are increasing in Canada, 1 and family physicians remain the main point of primary care for people with diabetes. 2 The challenge for physicians in this context is to design realistic treatment plans and negotiate priorities to maximize health benefits for these patients. This article summarizes recommendations from the Canadian Diabetes Association (CDA) 2008 clinical practice guidelines (CPGs). The guidelines are available on-line at cpg/. This review covers the care of adults with type 2 diabetes and gives particular attention to new recommendations. To assist with readability, grading and evidence levels have been simplified to single letters (eg, grade A recommendation = [A]). Table 1 summarizes the grading system used by the CDA. Table 1. Criteria for assigning levels of evidence and grades to recommendations for clinical practice GRADE OR LEVEL CRITERIA Grade A The best evidence is level 1 Level 1A Level 1B Systematic overview or meta-analysis of highquality randomized controlled trials or appropriately designed randomized controlled trial with adequate power to answer the question posed by the investigators Nonrandomized clinical trial or cohort study with indisputable results Grade B The best evidence is level 2 Level 2 Randomized controlled trial or systematic overview that does not meet level-1 criteria Grade C The best evidence is level 3 Level 3 Grade D Level 4 Nonrandomized clinical trial or cohort study The best evidence is level 4 or consensus Other Practice CPGs also suggested a more aggressive target of 6%, but 2 recent randomized controlled trials showed no macrovascular benefit to this target. The ACCORD trial demonstrated that a therapeutic strategy to lower the level of HbA 1c to < 6% in high-risk patients did not reduce the risk of macrovascular disease and, in fact, was associated with a small increase in mortality. 4 The ADVANCE trial did not show this increased mortality, but it also did not demonstrate macrovascular benefit of lowering the HbA 1c level below 6.5%; it did, however, show a reduction in nephropathy in the intensive-control group. 5 In contrast, the posttrial monitoring of the United Kingdom Prospective Diabetes Study (UKPDS- PTM) demonstrated a reduction in myocardial infarction and all-cause mortality in the subgroup with intensive glycemic control after a 10-year posttrial follow-up. 6 The key differences between the UKPDS-PTM and the ACCORD and ADVANCE trials are UKPDS-PTM s early intervention and longer follow-up. This suggests that earlier intervention has lasting benefit but that a target HbA 1c level of 7% is more appropriate in patients at high risk of vascular events who have had diabetes for a long time. Recommended targets for glycemic control 1. Patients should be treated to achieve a target HbA 1c level of 7% to reduce microvascular complications in all (A) and macrovascular complications in type 1 diabetes (C). 2. To reach an HbA 1c level of 7%, people with diabetes should aim for the following: fasting plasma glucose or preprandial plasma glucose target of mmol/l (B) and 2-hr postprandial plasma glucose target of mmol/l (B). 3. Further postprandial blood glucose lowering to mmol/l might be considered if HbA 1c targets are not reached with the postprandial target of mmol/l (D). Glycemic control and diabetes Targets for glycemic control. The new guidelines recommend a target hemoglobin A 1c (HbA 1c ) level of 7% for all patients with diabetes (A). A more aggressive target of 6.5% can be considered for some patients to help prevent microvascular complications, but this benefit must be weighed against an increase in mortality in patients at very high risk of cardiovascular (CV) events (A). The benefit of achieving the target HbA 1c level of 7% for microvascular risk reduction is well established. 3 The 2003 Monitoring glycemic control. Patients with type 2 diabetes taking once-daily insulin and oral antihyperglycemic agents should monitor their blood glucose at least once a day at different times (D), or more often if they are on multiple doses of insulin (C). Because there is contradictory evidence about the benefit of self-monitoring of blood glucose for patients who are not taking insulin, self-monitoring should be individualized according to the type of treatment and level of control (D). Vol 55: january janvier 2009 Canadian Family Physician Le Médecin de famille canadien 39
2 Pharmacologic management of type 2 diabetes. As more antihyperglycemic agents become available, careful consideration should be given to their advantages and disadvantages. Figure 1 summarizes the key points from the guidelines. Metformin remains the initial drug for type 2 diabetes, but the guidelines now support its use in all people with diabetes, irrespective of body weight (D). When glycemic targets are not met with metformin alone, 1 or more agents from a different class should be added to metformin. The choice of second-line agents depends on the desired (and undesired) characteristics of the treatment. The incretin agent, dipeptidyl peptidase-4 inhibitor, is a new option. In the presence of marked hyperglycemia (HbA 1c 9%), the 2008 CPGs recommend starting combination pharmacologic therapy immediately, concurrent with lifestyle changes (D). When basal insulin is added to antihyperglycemic agents, the guidelines recommend considering insulin analogues (eg, insulin detemir or insulin glargine) instead of neutral protamine Hagedorn (NPH) to reduce risk of nocturnal or symptomatic hypoglycemia (A). Cardiovascular risk and diabetes Cardiovascular disease (CVD) is the number 1 cause of death among those with diabetes. 7 Thus, a thorough assessment of CV risk and implementation of a treatment plan (if necessary) is essential for all patients with diabetes (D). Cardiovascular risk assessment. The degree of benefit of medical intervention is based on patients absolute risk of CV events, with higher-risk patients deriving greater benefit. 8 Thus, identifying those at high risk can ensure that those who are most likely to benefit will receive treatment. Age is among the strongest predictors of risk, so the CDA recommends that men 45 years and older and women 50 years and older should be considered high risk. Patients below these age cutoffs, but meeting any 1 of the other important CV risk factors, should also be considered high risk. Vascular protection. People with diabetes develop vascular disease approximately 15 years earlier than people without diabetes. 9 The concept of vascular protection was introduced in the 2003 CPGs, but it has been further stratified in the 2008 version, owing to evidence that shows a comprehensive multifactorial approach to vascular protection substantially reduces complications. 10,11 All patients with diabetes should receive interventions to reach target blood pressure (BP) of < 130/80 mm Hg and HbA 1c levels of 7%, to stop smoking, and to maintain healthy diets, physical activity, and healthy body Figure 1. Pharmacologic management of type 2 diabetes Symptomatic hyperglycemia with metabolic decompensation Clinical assessment HbA 1c < 9.0% HbA 1c 9.0% Initiate lifestyle interventions (eg, nutrition therapy, physical activity) If no change in 3 months Initiate insulin with or without metformin Initiate metformin If NOT at target Initiate metformin and lifestyle interventions concurrently Consider initiating combination therapy: metformin and another agent from a different class, including insulin, or insulin in symptomatic individuals Add an agent best suited to your patient (see advantages and disadvantages below) Agent HbA 1c * Advantages Disadvantages Sulfonylurea improved postprandial control associated hypoglycemia newer sulfonylureas are associated requires 3-4 doses daily with less hypoglycemia weight gain TZD durable monotherapy 6-12 wk for maximal effect rare hypoglycemia weight gain edema, rare CHF, rare fractures in females -Glucosidase improved postprandial control GI side effects inhibitor (acarbose) weight neutral rare hypoglycemia Insulin no dose ceiling weight gain many types, flexible regimes associated hypoglycemia in HbA 1c DPP-4 inhibitor to improved postprandial control new agent (long-term safety not known) weight neutral Weight-loss agent weight loss GI side effects (orlistat) no hypoglycemia increased heart rate, BP (sibutramine) If still NOT at target Add another agent Add bedtime basal insulin to other agent(s) Intensify insulin regimen Timely adjustments or additions of antiglycemic agents should be made to attain target HbA 1c within 6-12 mo BP blood pressure, CHF congestive heart failure, DPP-4 dipeptidyl peptidase-4, GI gastrointestinal, TZD thiazolidinedione. * = <1.0% decrease, = 1.0%-2.0% decrease, = >2.0% decrease. 40 Canadian Family Physician Le Médecin de famille canadien Vol 55: january janvier 2009
3 Cardiovascular risk assessment recommendations 1. All patients with diabetes should be assessed for cardiovascular risk annually (D). 2. Patients with diabetes are considered high risk if they are male 45 y or female 50 y (B) or male < 45 y or female < 50 y with any of the following (D): - macrovascular or microvascular disease, - 2 or more cardiac risk factors (eg, first-degree relative with premature coronary or cerebrovascular disease, smoking, hypertension, dyslipidemia), - an extreme single risk factor (eg, systolic blood pressure > 180 mm Hg or low-density lipoprotein level > 5.0 mmol/l), or - diabetes for longer than 15 y and age > 30 y. weight. On top of these interventions, those found to be at high risk should be prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), 12 lipid-lowering medications (particularly statins), and possibly acetylsalicylic acid (ASA). It is important to note that ARBs are now included in the CPGs as an alternative to ACE inhibitors. Specific reference to statins is also new and reflects the growing literature on the benefits of these medications for high-risk groups. 13,14 Recommendations regarding ASA have also been modified, because ASA therapy has been shown to have less of a cardioprotective effect in patients with diabetes than in those without diabetes, and to have no benefit in primary prevention. 15,16 Thus, the 2008 CPGs state that low-dose ASA therapy (81 to 325 mg) could be considered in people with stable CVD (D) but clinical judgement should be exercised regarding its use in primary prevention (D). Recommendations for vascular protection 1. For vascular protection for all individuals with diabetes ([A] for patients older than 40 y with type 2 diabetes and microalbuminuria; [D] for all others), aim for the following: HbA 1c level 7.0% (see glycemic control), blood pressure < 130/80 mm Hg, smoking cessation, physical activity, healthy diet, and healthy body weight. 2. For high-risk patients, prescribe 1 or more of the following: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker ([A] for those with vascular disease; [B] for other high-risk groups), a lipid-lowering medication, particularly statins (see Treatment of dyslipidemia), or acetylsalicylic acid (for secondary prevention). Vol 55: january janvier 2009 Canadian Family Physician Le Médecin de famille canadien 41
4 Treatment of hypertension. Strict control of BP improves morbidity and mortality in patients with diabetes. 3,17-19 The CDA recommends that BP be measured at every visit and hypertension be diagnosed according to the national hypertension guidelines (www. hypertension.ca/chep). Treatment targets remain systolic BP < 130 mm Hg (C) and diastolic BP < 80 mm Hg (B). Clinical trials have shown that multiple medications and titrations are required to achieve these targets. 18,20 A summary of recommended first-line and combination medications is provided in Table 2, but it is important to note that ACE inhibitors and ARBs are given special consideration as first-line treatment agents because of their renal benefits (D) 12 and that a-blockers are not recommended as first-line agents for patients with diabetes (A). Table 2. Hypertension medication for patients with diabetes Diabetic Population Initial medications Additional medications BP 130/80 mm Hg or albuminuria Isolated systolic hypertension ACE inhibitor (A) ARB (A/B)* Thiazide-like diuretic (A) DHP CCB (B) ACE inhibitor (B) ARB (B) Thiazide-like diuretic (B) Long-lasting DHP CCB (C) Cardioselective b-blocker (B) Non DHP CCB (B) N/A ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker; DHP CCB dihydropyridine calcium channel blocker. *(B) for patients with non left ventricular hypertrophy; (A) for all others. Recommendations for treatment of dyslipidemia 1. Fasting lipid levels TC, HDL-C, TG, and LDL-C should be measured at the time of diagnosis and then every 1-3 y. 2. The primary target of therapy for adults is LDL-C (A); the secondary target is the TC/HDL-C ratio (D). 3. Adults at high risk of vascular events should be treated with statins to achieve LDL-C levels 2.0 mmol/l (A). 4. TC/HDL-C ratio < 4.0 mmol/l should be targeted through glycemic control and lifestyle modification (D). 5. If TG levels are > 10 mmol/l, treat with a fibrate to prevent pancreatitis (D). Treatment of dyslipidemia. Dyslipidemia is a well-recognized risk factor for CVD. Fasting lipid levels should be measured at the time of diagnosis and every 1 to 3 years afterward (D). The primary target of therapy is the low-density lipoprotein cholesterol level (LDL-C) ( 2.0 mmol/l in patients at high risk [A]); the secondary target is the ratio of total cholesterol (TC) to high-density lipoprotein cholesterol (HDL-C) (< 4 mmol/l in patients at high risk [D]). Statins are the first-line treatment for dyslipidemia in patients with diabetes. If targets cannot be achieved with statins alone, combination therapy with ezetimibe, fibrate, or niacin can be considered (B), although there are no completed trials demonstrating clinical outcomes. Hypertriglyceridemia (triglyceride levels > 10.0 mmol/l) should be treated with fibrates to reduce the risk of pancreatitis (D). Recommendations for treatment of hypertension 1. Blood pressure (BP) should be measured at every diabetes clinic visit and hypertension should be diagnosed according to the national hypertension guidelines (D). 2. Treatment should target BP < 130/80 mm Hg ([C] for systolic BP; [B] for diastolic BP). 3. Most people require multiple BP-lowering medications to reach BP targets. Pharmacologic recommendations are summarized in Table Lifestyle interventions to reduce BP (eg, healthy weight, low sodium intake) should be encouraged alongside pharmaceutical interventions (D). Screening for coronary artery disease. Asymptomatic cardiac ischemia is common among those with diabetes. Many patients who present with myocardial infarction have no preceding symptoms. To identify those with established coronary artery disease in the absence of symptoms, the 2008 CPGs recommend that baseline electrocardiograms be conducted in all individuals older than 40 years of age (D). Lifestyle modification and diabetes Lifestyle modifications are important for treatment and prevention of diabetes. Many of the 2008 recommendations on nutrition and exercise are the same as or similar to those in the 2003 guidelines. One new recommendation is that patients be referred to and supported by exercise specialists. Structured physical activity counseling by health care providers increases physical activity and produces modest, sustained weight loss ; the effects of simply recommending that patients exercise more, which most clinicians do, are less certain. 25 Conclusion Clinical practice guidelines are designed to enable health care providers to engage with the evidence and better apply it in their practices. For conditions like type 2 diabetes, which are complex and multidimensional, treatment plans should be developed and discussed with patients. This might require stepwise introduction of various treatments and tests, and continued patient 42 Canadian Family Physician Le Médecin de famille canadien Vol 55: january janvier 2009
5 education, so that patients understand the value that each intervention has for optimizing their health. Dr Bhattacharyya is a Clinician Scientist at the Li Ka Shing Knowledge Institute of St Michael s Hospital in Toronto, Ont; an Assistant Professor in the Department of Family and Community Medicine and the Department of Health Policy, Management, and Evaluation at the University of Toronto; and a member of the Executive Committee of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA) (2008). Ms Estey is Research Coordinator at the Li Ka Shing Knowledge Institute. Dr Cheng is an endocrinologist at Credit Valley Hospital and St Michael s Hospital and an Assistant Professor (adjunct) in the Department of Medicine at the University of Toronto. Competing interests Dr Bhattacharyya is on the executive committee of the clinical and scientific section of the Canadian Diabetes Association (CDA) and on the Guideline Dissemination and Implementation Committee of the CDA. Dr Cheng served on the expert and steering committees for the CDA 2008 guidelines. References 1. Public Health Agency of Canada. National diabetes fact sheet. Canada Ottawa, ON: Public Health Agency of Canada; Available from: Accessed 2008 Dec Jaakkimainen L, Shah BR, Kopp A. Sources of physician care for people with diabetes. In: Hux JE, Booth GL, Slaughter PM, Laupacis A, editors. Diabetes in Ontario: an ICES practice atlas. Toronto, ON: Institute for Clinical Evaluative Sciences; UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131): Erratum in: Lancet 1999;354(9178): Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24): The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24): Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15): Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. Diabetes Care 2006;29(1): Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual s absolute cardiovascular risk. Lancet 2005;365(9457): Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368(9529): Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6): Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5): ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435): Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493): Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329): ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268(10): Schmittdiel J, Vijan S, Fireman B, Lafata JE, Oestreicher N, Selby JV. Predicted quality-adjusted life years as a composite measure of the clinical value of diabetes risk factor control. Med Care 2007;45(4): UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160): CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287(19): Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165(12): Petrella RJ, Koval JJ, Cunningham DA, Paterson DH. Can primary care doctors prescribe exercise to improve fitness? The Step Test Exercise Prescription (STEP) project. Am J Prev Med 2003;24(4): Kirk A, Mutrie N, MacIntyre P, Fisher M. Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with type 2 diabetes. Diabetologia 2004;47(5): Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler L, Oneida B, et al. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care 2004;27(7): Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005;(2):CD Harris SB, Petrella RJ, Leadbetter W. Lifestyle interventions for type 2 diabetes. Relevance for clinical practice. Can Fam Physician 2003;49: Vol 55: january janvier 2009 Canadian Family Physician Le Médecin de famille canadien 43
Diabetes mellitus is a chronic condition that requires
CMAJ Review Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines Onil K. Bhattacharyya MD PhD, Baiju R. Shah MD PhD, Gillian L. Booth MD MSc
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationThe New Diabetes Standard of Care: More Than Just Glycemic Control. Copyright
CLINICAL Viewpoint The New Diabetes Standard of Care: More Than Just Glycemic Control Advancement in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationCardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationCanadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Executive Summary
Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Executive Summary Canadian Diabetes Association Clinical Practice Guidelines Expert
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More informationClinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationEducational and behavioral interventions hitherto published
Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira,
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationDiabetes and. Cardiovascular Disease. among Older Adults: An Update on the Evidence. Cardiovascular Disease. Diabetes as a Risk Factor for
Cardiovascular Disease Diabetes and Cardiovascular Disease among Older Adults: An Update on the Evidence Pamela Katz, MD, Department of Endocrinology and Metabolism, University of Toronto, Toronto, ON.
More informationAACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM
AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 TASK FORCE Alan J. Garber, MD, PhD, FACE, Chair Martin J. Abrahamson, MD Joshua I. Barzilay, MD, FACE Lawrence Blonde, MD, FACP, FACE Zachary T. Bloomgarden,
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationRenal Protection Staying on Target
Update Staying on Target James Barton, MD, FRCPC As presented at the University of Saskatchewan's Management of Diabetes & Its Complications (May 2004) Gwen s case Gwen, 49, asks you to take on her primary
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationLow HDL C and/or elevated triglycerides (TG) was seen in nearly two thirds of MI patients
PRESS RELEASE New Insights Link Low HDL Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL Cholesterol Surveys establish residual
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationDiabetes is a chronic illness that requires
P O S I T I O N S T A T E M E N T Standards of Medical Care for Patients With Diabetes Mellitus AMERICAN DIABETES ASSOCIATION Diabetes is a chronic illness that requires continuing medical care and patient
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationEffective Health Care
Number 8 Effective Health Care Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes Executive Summary Background Type 2 diabetes is characterized by insulin
More information